Novel regulation of type IV collagenase (matrix metalloproteinase-9 and -2) activities by transforming growth factor-β1 in human prostate cancer cell lines

Molecular Biology of the Cell

Volumn 10, Issue 2, 1999, Pages 407-416

  Sehgal, Inder ^a   Thompson, Timothy C ^a  

^a BAYLOR COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ENZYME PRECURSOR; GELATINASE A; GELATINASE B; METALLOPROTEINASE INHIBITOR; TRANSFORMING GROWTH FACTOR BETA1;

ARTICLE; CANCER CELL; CONTROLLED STUDY; ENZYME ACTIVITY; ENZYME INDUCTION; ENZYME INHIBITION; ENZYME REGULATION; ENZYME RELEASE; GENE EXPRESSION REGULATION; GENETIC STABILITY; GENETIC TRANSCRIPTION; HUMAN; HUMAN CELL; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN SYNTHESIS;

EID: 0032918016     PISSN: 10591524     EISSN: None     Source Type: Journal    
DOI: 10.1091/mbc.10.2.407     Document Type: Article

References (53)

1. Ahrens, D., Koch, A.E., Pope, R.M., Stein-Picarella, M., and Niedbala, M.J. (1996). Expression of matrix metalloproteinase 9 (96-kd gelatinase B) in human rheumatoid arthritis. Arthritis Rheum. 39, 1576-1587.
2. Albini, A., Melchiori, A., Santi, L., Liotta, L.A., Brown, P.D., and Stetler-Stevenson, W.G. (1991). Tumor cell invasion inhibited by TIMP-2. J. Natl. Cancer Inst. 83, 775-779.
3. Altus, M.S., and Nagamine, Y. (1991). Protein synthesis inhibition stabilizes urokinase-type plasminogen activator mRNA. J. Biol. Chem. 266, 21190-21196.
4. Ausubel, F.M., Brent, R., Kingston, R.E., Moore, D.D., Seidman, J.G., Smith, J.A., and Struhl, K. (1989). Current Protocols in Molecular Biology, vol. 1, New York: Greene/Wiley-Interscience.
5. Benbow, U., and Brinckerhoff, C.E. (1997). The AP-1 site and MMP gene regulation: what is all the fuss about? Matrix Biol. 15, 519-526.
6. Bernhard, E.J., Gruber, S.B., and Muschel, R.J. (1994). Direct evidence linking expression of matrix metalloproteinase 9 (92-kDa gelatinase/collagenase) to the metastatic phenotype in transformed rat embryo cells. Proc. Natl. Acad. Sci. USA 91, 4293-4297.
7. Bohjanen, P.R., Petryniak, B., June, C.H., Thompson, C.B., and Lindsten, T. (1992). AU RNA-binding factors differ in their binding specificities and affinities. J. Biol. Chem. 267, 6302-6309.
8. Brooks, P.C., Silletti, S., von Schalscha, T.L., Friedlander, M., and Cheresh, D.A. (1998). Disruption of angiogenesis by PEX, a noncatalytic metalloproteinase fragment with integrin binding activity. Cell 92, 391-400.
9. Brown, P.D., Levy, A.T., Margulies, I.M.K., Liotta, L.A., and Stetler-Stevenson, W.G. (1990). Independent expression and cellular processing of Mr 72,000 type IV collagenase and interstitial collagenase in human tumorigenic cell lines. Cancer Res. 50, 6184-6191.
10. Edwards, D.R., Murphy, G., Reynolds, J.J., Whitham, S.E., Docherty, A.J.P., Angel, P., and Heath, J.K. (1987). Transforming growth factor β modulates the expression of collagenase and metalloproteinase inhibitor. EMBO J. 6, 1899-1904.
11. Egawa, S., Kadmon, D., Miller, G.J., Scardino, P.T., and Thompson, T.C. (1992). Alterations in mRNA levels for growth-related genes after transplantation into castrated hosts in oncogene-induced clonal mouse prostate carcinoma. Mol. Carcinog. 5, 52-61.
12. Farina, A.R., Tacconelli, A., Teti, A., Gulino, A., and Mackay, A.R. (1998). Tissue inhibitor of metalloproteinase-2 protection of matrix metalloproteinase-2 from degradation by plasmin is reversed by divalent cation chelator EDTA and the bisphosphonate alendronate. Cancer Res. 58, 2957-2960.
13. Fowlkes, J.L., Enghild, J.J., Suzuki, K., and Nagase, H. (1994). Matrix metalloproteinases degrade insulin-like growth factor-binding protein-3 in dermal fibroblast cultures. J. Biol. Chem. 269, 25742-25746.
14. Fridman, R., Toth, M., Pena, D., and Mobashery, S. (1995). Activation of progelatinase B (MMP-9) by gelatinase A (MMP-2). Cancer Res. 55, 2548-2555.
15. Gearing, A.J., et al. (1994). Processing of tumor necrosis factor-α precursor by metalloproteinases. Nature 370, 555-557.
16. Gianluigi, G., Falk-Marzillier, J., Schiraldi, O., Stetler-Stevenson, W.G., and Quaranta, V. (1997). Induction of cell migration by matrix metalloprotease-2 cleavage of laminin-5. Science 277, 225-228.
17. Greene, G.F., Kitadai, Y., Pettaway, C.A., von Eschenbach, A.C., Bucana, C.D., and Fidler, I.J. (1997). Correlation of metastasis-related gene expression with metastatic potential in human prostate carcinoma cells implanted in nude mice using an in situ mRNA hybridization technique. Am. J. Pathol. 150, 1571-1582.
18. Gum, R., Lengyel, E., Juarez, J., Chen, J.H., Sato, H., Seiki, M., and Boyd, D. (1996). Stimulation of 92-kDa gelatinase B promoter activity by ras is mitogen-activated protein kinase kinase 1-independent and requires multiple transcription factor binding sites including closely spaced PEA3/ets and AP-1 sequences. J. Biol. Chem. 271, 10672-10680.
19. Hujanen, E.S., Vaisanen, A., Zheng, A., Tryggvason, K., and Turpeenniemi-Hujanen, T. (1994). Modulation of Mr 72,000 and Mr 92,000 type-IV collagenase (gelatinase A and B) gene expression by interferons a and gamma in human melanoma. Int. J. Cancer 58, 582-586.
20. Keeton, M.R., Curriden, S.A., van Zonneveld, A.-J., and Loskutoff, D.J. (1991). Identification of regulatory sequences in the type 1 plasminogen activator inhibitor gene responsive to transforming growth factor β. J. Biol. Chem. 266, 23048-23052.
21. Kondapaka, S.B., Fridman, R., and Reddy, K.B. (1997). Epidermal growth factor and amphiregulin up-regulate matrix metalloproteinase-9 (MMP-9) in human breast cancer cells. Int. J. Cancer. 70, 722-726.
22. Koolwijk, P., Miltenburg, M., van Erck, G., Oudshoorn, M., Niedbala, M.J., Breedveld, F.C., and van Hinsberg, V.W. (1995). Activated gelatinase-B (MMP-9) and urokinase-type plasminogen activator in synovial fluids of patients with arthritis. J. Rheumatol. 22, 385-393.
23. Laiho, M., DeCaprio, J.A., Ludlow, J.W., Livingston, D.M., and Massague, J. (1990). Growth inhibition by TGF-β linked to suppression of retinoblastoma protein phosphorylation. Cell 62, 175-185.
24. Levi, E., Fridman, R., Miao, H.-Q., Ma, Y-S., Yayon, A., and Vlodavsky, I. (1996). Matrix metalloproteinase 2 releases active soluble ectodomain of fibroblast growth factor receptor 1. Proc. Natl. Acad. Sci. USA 93, 7069-7074.
25. Liotta, L.A., Steeg, P.S., and Stetler-Stevenson, W.G. (1991). Cancer metastasis and angiogenesis: an imbalance of positive and negative regulation. Cell 64, 327-336.
26. Lyons, J.G., Birkedal-Hansen, B., Pierson, M.C., Whitelock, J.M., and Birkedal-Hansen, H. (1993). Interleukin-1β and transforming growth factor-α/epidermal growth factor induce expression of Mr 95,000 type IV collagenase/gelatinase and interstitial fibroblast-type collagenase by rat mucosal keratinocytes. J. Biol. Chem. 268, 19143-19151.
27. Lyons, R.M., Gentry, L.E., Purchio, A., and Moses, H.L. (1990). Mechanism of activation of latent recombinant transforming growth factor β1 by plasmin. J. Cell Biol. 110, 1361-1367.
28. Marti, H.P., Lee, L., Kashgarian, M., and Lovett, D.H. (1994). Transforming growth factor-β1 stimulates glomerular mesangial cell synthesis of the 72-kd type IV collagenase. Am. J. Pathol. 144, 82-94.
29. Matrisian, L.M. (1990). Metalloproteinases and their inhibitors in matrix remodeling. Trends Genet. 6, 121-125.
30. Mazzieri, R., Masiero, L., Zanetta, L., Monea, S., Onisto, M., Garbisa, S., and Mignatti, P. (1997). Control of type IV collagenase activity by components of the urokinase-plasmin system: a regulatory mechanism with cell-bound reactants. EMBO J. 16, 2319-2332.
31. Murphy, G., and Knauper, V. (1997). Relating matrix metalloproteinase structure to function: why the "hemopexin" domain? Matrix Biol. 15, 511-518.
32. Nagamine, Y., Sudol, M., and Reich, E. (1983). Hormonal regulation of plasminogen activator mRNA production in porcine kidney cells. Cell 32, 1181-1190.
33. Okada, Y., Tsuchiya, H., Shimizu, H., Tomita, K., Nakanishi, I., Sato, H., Seiki, M., Yamashita, K., and Hayakawa, T. (1990). Induction and stimulation of 92-kDa gelatinase/type IV collagenase production in osteosarcoma and fibrosarcorna cell lines by tumor necrosis factor α. Biochem Biophys. Res. Commun. 171, 610-617.
34. Overall, C.M., Wrana, J.L., and Sodek, J. (1991). Transcriptional and posttranscriptional regulation of 72-kDa gelatinase/Type IV collagenase by transforming growth factor-β1 in human fibroblasts. J. Biol. Chem. 266, 14064-14071.
35. Patterson, B.C., and Sang, Q.A. (1997). Angiostatin-converting enzyme activities of human matrilysin (MMP-7) and gelatinase B/type IV collagenase (MMP-9). J. Biol. Chem. 272, 28823-28825.
36. Penttinen, R.P., Kobayashi, S., and Bornstein, P. (1988). Transforming growth factor β increases mRNA stability for matrix proteins in both the presence and in the absence of changes in mRNA stability. Proc. Natl. Acad. Sci. USA 85, 1105-1108.
37. Ren, C., Yang, G., Timme, T.L., Wheeler, T.M., and Thompson, T.C. (1998). Reduced lysyl oxidase mRNA levels in experimental and human prostate cancer. Cancer Res. 58, 1285-1290.
38. Ross, J. (1995). mRNA stability in mammalian cells. Microbiol. Rev. 59, 423-450.
39. Sambrook, J., Fritsch, E.F., and Maniatis, T. (1989). Molecular Cloning: A Laboratory Manual, 2nd ed., Cold Spring Harbor, NY: Cold Spring Harbor Laboratory.
40. Samuel, S.K., Hurta, R A.R., Kondaiah, P., Khalil, N., Turley, E.A., Wright, J.A., and Greenberg, A.H. (1992). Autocrine induction of tumor protease production and invasion by a metallothionein-regulated TGF-β1 (Ser223, 225). EMBO J. 11, 1599-1605.
41. Sato, H., Kita, M., and Seiki, M. (1993). v-Src activates the expression of 92-kDa type IV collagenase gene through the AP-1 Site and the GT box homologous to retinoblastoma control elements. J. Biol. Chem. 268, 23460-23468.
42. Sato, H., and Seiki, M. (1993). Regulatory mechanism of 92 kDa type IV collagenase gene expression which is associated with invasiveness of tumor cells. Oncogene 8, 395-405.
43. Seed, B., and Sheen, J.-Y. (1988). A simple phase-extraction assay for chloramphenicol acyltransferase activity. Gene 67, 271-277.
44. Sehgal, G., Hua, J., Bernhard, E.J., Sehgal, I., Thompson, T.C., and Muschel, R.J. (1998). Requirement for matrix metalloproteinase-9 (gelatinase B) expression in metastasis by murine prostate carcinoma. Am. J. Pathol. 152, 591-596.
45. Sehgal, I., Baley, P., and Thompson, T.C. (1996). Transforming growth factor β1 stimulates contrasting responses in metastatic versus primary mouse prostate cancer-derived cell lines in vitro. Cancer Res. 56, 3359-3365.
46. Shaw, G., and Kamen, R. (1986). A conserved AU sequence from the 3′ untranslated region of GM-CSF mRNA mediates selective mRNA degradation. Cell 46, 659-667.
47. Singh, R.K., Gutman, M., Reich, R., and Bar-Eli, M. (1995). UV B irradiation promotes tumorigenic and metastatic properties in primary cutaneous melanoma via induction of interleukin 8. Cancer Res. 55, 3669-3674.
48. Stearns, M.E., and Stearns, M. (1996). Immunohistochemical studies of activated matrix metalloproteinase-2 (MMP-2a) expression in human prostate cancer. Oncol. Res. 8, 63-67.
49. Stefanovic, B., Hellerbrand, C., Holcik, M., Briendl, M., Liebhaber, S., and Brenner, D.A. (1997). Posttranscriptional regulation of collagen γ1(I) mRNA in hepatic stellate cells. Mol. Cell. Biol. 17, 5201-5209.
50. Timme, T.L., Yang, G., Rogers, E., Kadmon, D., Morganstern, J.P., Park, S.H., and Thompson, T.C. (1996). Retroviral transduction of transforming growth factor-β1 induces pleiotropic benign prostatic growth abnormalities in mouse prostate reconstitutions. Lab. Invest. 74, 747-760.
51. Welch, D.R., Fabra, A., and Nakajima, M. (1990). Transforming growth factor β stimulates mammary adenocarcinoma cell invasion and metastatic potential. Proc. Natl. Acad. Sci. USA 87, 7678-7682.
52. Woessner, J.F., Jr. (1991). Matrix metalloproteinases and their inhibitors in connective tissue remodeling. FASEB J. 5, 2145-2154.
53. Wood, M., Fudge, K., Mohler, J.L., Frost, A.R., Garcia, F., Wang, M., and Stearns, M.E. (1997). In situ hybridization studies of metalloproteinases 2 and 9 and TIMP-1 and TIMP-2 expression in human prostate cancer. Clin. Exp. Metastasis 15, 246-258.